|
At present, the therapy of the hemophilia A is
based on a substitutive treatment consisting of intravenous
administration of concentrates of FVIII. The development of
inhibitor antibodies, which neutralize the infused FVIII, currently
represents the main complication of the therapy of hemophilia,
making in some cases the substitutive treatment completely ineffective.
The factors facilitating the development of the inhibitor antibodies
could be linked with the therapy (e.g. blood transfusion) or
the patient (e.g. age, type of the mutation that caused hemophilia,
activation of the immunity system).
| The aims of this
project are: |
| |
- investigating the correlation between
the type of the mutation and the risk of the inhibitor's
development. |
| |
|
| |
- studying the role of the gene involved
in the immune response, such as class I and II MHC, in the
development of the inhibitor. |
| |
| We expect that the
results of this project will help us understand the molecular
mechanisms that cause the development of the inhibitor,
making thus possible to predict the risk of its occurrence
depending on the therapy administered to an individual with
certain known molecular flaws. |
|
